1 / 41

SCHIZOPRENIA

SCHIZOPRENIA. DEVELOPED COUNTRIES ROCHESTER, NY MOSCOW, RUSSIA AARHUS, DENMARK. DEVELOPING COUNTRIES AGRA, INDIA CALI, COLUMBIA IBADAN, NIGERIA. Incidence of SCHIZOPHRENIA: World Health Organization (1992). RESULTS: INCIDENCE OF SCHIZOPHRENIA IS SIMILAR ACROSS ALL CITIES.

ziv
Download Presentation

SCHIZOPRENIA

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SCHIZOPRENIA

  2. DEVELOPED COUNTRIES ROCHESTER, NY MOSCOW, RUSSIA AARHUS, DENMARK DEVELOPING COUNTRIES AGRA, INDIA CALI, COLUMBIA IBADAN, NIGERIA Incidence of SCHIZOPHRENIA: World Health Organization (1992) RESULTS:INCIDENCE OF SCHIZOPHRENIA IS SIMILAR ACROSS ALL CITIES

  3. SOME STATISTICS: • 1% OF U.S. POPULATION • 1 in 3 PSYCHIATRIC HOSPITAL BEDS • $65 BILLION • DIRECT TREATMENT • SOCIETAL COSTS • hospitals and institutions • law enforcement and judicial system • FAMILY COSTS

  4. POSITIVE SYMPTOMS THOUGHT DISORDERS DELUSIONS-BELIEFS CONTRARY TO FACTS PERSECUTION GRANDEUR CONTROL BY OTHERS PARANOIA HALLUCINATIONS Auditory most common NEGATIVE SYMPTOMS FLATTENED EMOTIONAL RESPONSES POVERTY OF SPEECH LACK OF INITIATIVE SOCIAL WITHDRAWAL INABILITY TO EXPERIENCE PLEASURE COGNITIVE DYSFUNCTIONS TWO CATEGORIES OF SYMPTOMS:

  5. NEGATIVE SYMPTOMS • These symptoms are similar to those observed in people with FRONTAL LOBE DAMAGE. • NEUROLOGICAL DISORDERS • Catatonia • Abnormal visual pursuit • Staring, no eye contact with others • Altered blinking (too much or not at all) • Poor pupillary reflex

  6. EVIDENCE FOR A BIOLOGICAL BASIS FOR SCHIZOPHRENIA? • GENETIC DATA • PHARMACOLOGICAL DATA • BRAIN IMAGING DATA • DEVELOPMENTAL DATA

  7. WHAT IS THE EVIDENCE? • GENETICS

  8. THE GENETICS OF SCHIZOPHRENIA • FAMILY STUDIES • TWIN STUDIES • MONOZYGOTIC TWINS ~ identical twins • DIZYGOTIC ~ fraternal twins • CONCORDANT  both twins SCHZO. • DISCORDANT  one twin SCHZO. • ADOPTION STUDIES

  9. Kety (1994) • Denmark Adoptee Studies 1. 5.6% of the relatives of schizophenics were diagnosed with schizo. or latent schizo. 2.0.9 %of the relatives of normal adoptees were diagnosed with these disorders 3. Schizo. More common in 1st degree relatives - Schizophrenia in 1st degree relatives = 12% - Schizophrenia in 2nd degree relatives = 2.2% 4. Biological relatives of schizophrenics show no increased rate of other mental disorders

  10. IMPORTANT POINTS TO REMEMBER FROM TWIN STUDIES: • SCHIZOPHRENIA has a genetic component. • Genetics, however, is not the whole story. Concordance rate far less than 100%. • Genetics may predispose an individual to developing SCHIZOPHRENIA. • Environmental factors may interact with genetics to increase susceptibility. • Therefore, there must be “unexpressed, dormant, schizophrenic genes”

  11. PHARMACOLGICAL DATA: THE DOPAMINE HYPOTHESIS • Origins of antipsychotic drug development: • Laborit ~ accidentally found that antihistamines reduced anxiety in presurgical patients. • Charpentier ~ chlorpromazine “quieted hyperactive” mental patients & “activated withdrawn” mental patients. • Since the early drugs (e.g., chlorpromazine and reserpine) produced Parkinsonian effects, these drugs were believed to act on the dopamine system.

  12. ADDITIONAL EVIDENCE FOR THE DOPAMINE HYPOTHESIS Cocaine, amphetamine, L-Dopa Positive Symptoms of Schizophrenia (blocked by antipsychotics) Suggestion: Antipsychotics = dopamine receptor antagonists (neuroleptics)

  13. SNYDER (1976,1978) • Examined the ability of antipsychotic (neuroleptic) drugs to bind to dopamine receptors. • Examined the relationship of a drug’s receptor binding affinity with its potency to reduce schizophrenic symptoms.

  14. SNYDER (1976, 1978) • Extracted neostriatum from calf brains - neurons contain dopamine receptors • Exposed neurons to radioactive dopamine • Washed away unbound dopamine • Measured amount of radioactivity in the neostriatum = measure of dopamine receptor binding • Measured the ability of various antipsychotics to block the binding of radioactive dopamine.

  15. SNYDER (1976, 1978) • RESULTS: • Highly clinically effective antipsychotics had a high binding affinity for dopamine receptors. • Less effective antipsychotics had a lower affinity. • One exception = Haloperidol - highly clinically effective for schizophrenia - low binding affinity to striatal dopamine receptors

  16. The Haloperidol Puzzle • Striatal Neurons mostly D1 receptors • Chlorpromazine binds to D1 and D2 receptors • Haloperidol binds preferentially to D2 receptors • Chlorpromazine = Phenothiazines = D1, D2 • Haloperidol = Butyrophenones = D2 selective

  17. The Dopamine Receptors • D1 • D2a • D2b • D3 • D4 Clozapine binds to D4 receptors • D5 Clozapine = an atypical neuroleptic. No Parkinsonian side effects. High binding to D4 Haloperidol binds best to D2 receptors

  18. WHAT IS WRONG WITH THE DOPAMINERGIC SYNAPSE IN SCHIZOPHRENICS? • POSSIBILITIES: 1. Increased release of dopamine? - More excitatory input to dopamine-containing neurons - Fewer or defective autoreceptors on dopamine neuron 2. Overabundance of dopamine receptors on post-synaptic neuron? - more response in postsynaptic neuron to dopamine receptor activation

  19. Where are the dopaminergic abnormalities located? • The Neostriatum? • Amygdala? • Frontal cortex? • Nucleus accumbens? - D4 receptors located here

  20. The Nucleus Accumbens • Are reinforcement/reward and schizophrenia related? -If reinforcement mechanisms are active at inappropriate times, then inappropriate behaviors (e.g., delusional thoughts) may be reinforced. • -Elation/euphoria reported to occur at onset of schizophrenic episode.

  21. BRAIN ABNORMALITIES AND SCHIZOPHRENIA • Since typical antipsychotics DO NOT alleviate negative symptoms associated with schizophrenia • and the negative symptoms are similar to those produced by frontal lobe damage • …Then, maybe frontal lobe dysfunction contributes to the negative symptoms of schizophrenia.

  22. Weinberger (1980’s – present) • Studied discordant identical twins: • SCHIZOPHRENIC twin showed enlarged ventricles in 16 of 17 pairs. • SCHIZOPHRENICS, in general, have larger ventricular to brain ratios (i.e., larger ventricles, less brain).

  23. Weinberger (1992) • Wisconsin Card Sorting Task (WCST) • WCST activates the lateral prefrontal lobe • Patients with lateral prefrontal lobe damage Deficient in WCST • Identical twins: discordant for SCHIZOPHRENIA • PET scan during WCST

  24. Weinberger, 1992 - WCST

  25. Weinberger (1992) RESULTS: • SCHIZOPHRENIC twin impaired on task, just like people with prefrontal lobe damage • SCHIZOPHRENIC twin shows hypoactivity in frontal lobe (decrease blood flow vs. unaffected twin) • Many SCHIZOPHRENICS are impaired on task and show frontal lobe hypoactivity

  26. Wolkin etal. (1992) • Correlated the NEGATIVE SYMPTOMS with FRONTAL LOBE metabolism (e.g., activity) in SCHIZOPHRENIC patients. • RESULTS: The more severe the negative symptoms, the less the metabolism (activity) • However, NO GROSS STRUCTURAL ABNORMALITIES in SCHIZOPHRENICS!!!!!!

  27. WHAT ARE THE CAUSES OF hypoFRONTALITY? • Abnormality in the development of frontal lobe?

  28. Benes etal. (1986,1991) Took a closer look at the cells in the FRONTAL CORTEX… SCHIZOPHRENIC BRAINS vs NORMAL BRAINS:

  29. Benes etal. (1991) • Abnormally LOW number of neurons in LAYERS I and II (outer layers) of the FRONTAL CORTEX. • Abnormally HIGH number of neurons in LAYER V (deep layers)of the FRONTAL CORTEX. • Suggest: Abnormalities NOT due to degeneration (since levels of glia cells normal) but due to DEVELOPMENTAL abnormalities.

  30. WHAT DEVELOPMENTAL FACTOR(S) MAY CAUSE BRAIN ABNORMALITY? • A VIRUS? • GENETIC ABNORMALITY? • AN INTERACTION OF THE TWO?

  31. Epidemiological Evidence for an Environment influence • Mednick (1988) - Helsinki, Finland -1957 ~ Asian Flu Epidemic (Virus) - Higher incidence of SCHIZOPHRENIA in fetuses carried during the epidemic vs. before epidemic - KEY POINT: Fetuses whose mothers developed the Flu during the 2nd trimester of pregnancy had highest incidence of schizophrenia as adults

  32. WHAT HAPPENS DURING THE 2ND TRIMESTER OF PREGNANCY? • Marked development of the neocortex • Cortex develops inside out: • Cells migrate to deep layers 1st. • Cells of the outer layers must migrate through deep layers). • In the SCHIZOPHRENIC brain, cells destined to be the outer layers of the cortex get STUCK and never make it there.

  33. ADDITIONAL SUPPORT FOR DEVELOPMENTAL FACTORS…Brach etal. (1992) • “CHRONO MARKERS” OR “FOSSILS” OF 2ND TRIMESTER development: CORTEX AND FINGER TIP DERMAL CELL MIGRATION • Studied:MONOZYGOTIC TWINS - NON-SCHIZOPHRENIC PAIRS (n=7) - SCHIZOPHRENIC DISCORDANT PAIRS (n=23) • Measured:INTRA-TWIN DIFFERENCES IN FINGER TIP RIDGE PATTERNS

  34. Brach etal. (1992) • RESULTS: - NON-SCHIZOPHRENIC TWINS ALL HAVE SAME FINGER PRINTS (not a lot of differences). - TWINS DISCORDANT FOR SCHIZOPHRENIA have different finger prints!

  35. Brach etal. (1992) CONCLUDE: - During the 2nd trimester of pregnancy, something in the “environment” may have differentially affected one twin but not the other. - Maybe it was a virus, but we still don’t have the answer…

  36. IN SUMMARY: • SCHIZOPHRENIA IS A BIOLOGICAL DISEASE THAT MAY INVOLVE DISRUPTION OF MANY SYSTEMS • FRONTAL CORTEX • DOPAMINE SYSTEMS • GENETIC, ENVIRONMENTAL AND DEVELOPMENTAL FACTORS ARE IMPORTANT FOR THE GENISIS OF THE DISEASE

  37. An Animal Model of Schizophrenia?? • Phencyclidine (PCP) – “angel dust” • Single ingestion transient schizo. symptoms • Chronic use long lasting schizo. symptoms - social withdrawal - flattened emotional responses - hallucinations - thought disorders - delusions, paranoia - Cognitive dysfunction, hypofrontality

  38. Jentsch etal. (1997) • Effects of chronic PCP exposure in monkey - twice/day for 14 days • Measured: - cognition dependent on normal frontal lobe dopamine levels - frontal lobe dopamine utilization • Task – “Object Retrieval with a Detour” task -transparent box with one open side -open side oriented to the front, right or left of monkey -box contains a treat -monkey retrieves treat from one orientation (front)

  39. Jentsch etal. – cont. - re-orient the box opening to left - monkey must redirect response without touching a closed side to be successful • Design: - give PCP or saline for two weeks, then stop treatment - administer task from 7-28 days later • Results: - PCP-treated monkeys showed perseveration when box is re-oriented. They keep making the original response

  40. Jentsch etal. – cont. • Important Points: - Deficits identical to those seen in monkeys w/ frontal lesions or frontal dopamine depletion - Deficits similar to those seen in schizophrenics or humans with frontal lobe lesions • Results: Dopamine Assay - chronic PCP decreases dopamine utilization in the prefrontal cortex

  41. Jentsch etal. – cont. • Dopamine antagonists exacerbate cognitive dysfunction in schizo. Suggests: - a subset of schizo. symptoms may be due to dopamine hypoactivity in frontal lobes Clozapine =atypical neuroleptic - improves performance of chronic PCP monkeys in object retrieval task -increases basal dopamine concentration in frontal cortex

More Related